Speclipse, a company specializing in laser and AI-based skin treatment and skin cancer diagnostics, announced on the 19th that it has accelerated its progress toward listing on the KOSDAQ market after receiving an A grade in a mock technical evaluation for technology-special listing.
In 2023, Speclipse completed its platform technology for manufacturing medical devices based on pulse lasers by merging with KL, a laser optics R&D company. Building on this, the company is focusing on laser-based medical devices for skin aesthetics and treatment, as well as skin cancer diagnostic devices. Its flagship products include 'PICO-K,' a beauty and treatment medical device utilizing a 300-picosecond laser; 'Spectra-Scope,' which uses laser spectroscopy technology and AI algorithms to diagnose skin cancer in real time without a biopsy; and 'DerMap,' an AI-based solution for tracking changes in skin lesions.
Currently, after the merger, the company has completed organizational restructuring and established a stable business system. Through synergy between the two companies, it has also strengthened its product portfolio, and, in particular, has secured the capability to manufacture all key laser components such as resonators and power supplies in-house. Based on this, in July 2024, the company successfully completed a 36 billion KRW Pre-IPO round with participation from K2 Investment, KB-Solidas Healthcare Investment Association, and Shinyoung-BSK Digital Innovation New Deal Investment Association.
After raising investment, Speclipse transitioned from a co-CEO system with Byun Sunghyun and Hong Junghwan to a sole CEO system under Hong Junghwan, achieving organic integration between business divisions and improving its profit structure. Former CEO Byun Sunghyun moved to the position of CTO (Chief Technology Officer), focusing on enhancing competitiveness in technology development and R&D, and successfully completing the PMI (Post-Merger Integration).
Tangible results have also become visible. In 2024, the company recorded sales of approximately 11.1 billion KRW, about three times higher than the previous year, and achieved a turnaround to profitability in just a year and a half after the merger. Its global market expansion strategy has also yielded results, with overseas sales accounting for 47.5% in 2024, and the company was awarded the 2 Million Dollar Export Tower. As a result, Speclipse's core technology and growth potential have been officially recognized externally with the A grade in the recent mock technical evaluation.
Hong Junghwan, CEO of Speclipse, stated, "By providing skin diagnosis and treatment solutions that combine AI and laser technology, we will grow into a global leader covering the entire spectrum from skin lesion diagnosis to treatment and aesthetics," adding, "We will successfully complete the technology-special listing and leap forward as a world-class total medical device company."
The company plans to pursue technology-special listing in the second half of this year, aiming for an IPO in 2026. Korea Investment & Securities has been selected as the lead underwriter for the listing.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
